Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Matrix metalloproteinase inhibitors

S M Wojtowicz-Praga1, R B Dickson, M J Hawkins

  • 1Georgetown University Hospital, Vincent T. Lombardi Cancer Center, Division of Medical Oncology, Washington, DC, USA.

Investigational New Drugs
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Employee stress claims: increasing implications for health promotion programming.

American journal of health promotion : AJHP·2011
Same author

Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis.

Oncogene·2008
Same author

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same author

Differential alteration of stem and other cell populations in ducts and lobules of TGFalpha and c-Myc transgenic mouse mammary epithelium.

Tissue & cell·2005
Same author

Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice.

British journal of cancer·2004
Same author

Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses.

British journal of cancer·2004
Same journal

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

Investigational new drugs·2026
Same journal

Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.

Investigational new drugs·2026
Same journal

Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes.

Investigational new drugs·2026
Same journal

Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia.

Investigational new drugs·2026
Same journal

Correction to: Prostate cancer cells' growth is decreased by novel MYC inhibitors.

Investigational new drugs·2026
Same journal

Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330.

Investigational new drugs·2026
See all related articles

Matrix metalloproteinases (MMPs) degrade extracellular matrix, aiding tumor invasion and metastasis. Inhibitors like marimastat and bryostatin-1 show promise as anti-cancer therapies by targeting MMP activity or production.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Matrix metalloproteinases (MMPs) are enzymes that degrade extracellular matrix components.
  • MMPs play crucial roles in tumor angiogenesis and metastasis.
  • An imbalance between MMPs and tissue inhibitors of metalloproteinases (TIMPs) is linked to cancer invasion.

Purpose of the Study:

  • To explore the therapeutic potential of targeting MMPs in cancer.
  • To review synthetic MMP inhibitors and their clinical development.
  • To investigate novel agents like bryostatins that modulate MMP production.

Main Methods:

  • Review of scientific literature on MMPs, TIMPs, and anti-cancer agents.
  • Discussion of synthetic MMP inhibitors (e.g., Batimastat, Marimastat).

Related Experiment Videos

  • Examination of bryostatins' mechanism of action, including protein kinase C (PKC) modulation.

    • Main Results:

    • Synthetic MMP inhibitors (Batimastat, Marimastat) show potent inhibition of MMPs.
    • Marimastat is orally available and in clinical trials.
    • Bryostatin-1 inhibits production of several MMPs by modulating PKC, and may affect TIMP-1 levels.

    Conclusions:

    • Targeting MMPs is a promising anti-cancer therapeutic strategy.
    • Synthetic MMP inhibitors and agents modulating MMP production represent potential new treatments.
    • Further research into MMP-targeted therapies is warranted.